Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Neoadjuvant for Organ Preservation in UC and RCC
NCT06427057Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label trial of cadonilimab in urothelial carcinoma (UC) and renal cell carcinoma (RCC) (2 cohorts), sponsored by Tongji Hospital. Primary endpoint: Bladder/Kidney Preservation Rate at 18 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
urothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06427057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427057.